ACTIVITY OF THE INTERFERON-INDUCED 2',5'-OLIGOADENYLATE SYNTHETASE IN PATIENTS WITH CHRONIC HEPATITIS-C

被引:26
作者
PAWLOTSKY, JM
HOVANESSIAN, A
ROUDOTTHORAVAL, F
LEBON, P
ROBERT, N
BOUVIER, M
BABANY, G
DUVAL, J
DHUMEAUX, D
机构
[1] INST PASTEUR,VIROL & CELLULAR IMMUN UNIT,F-75724 PARIS,FRANCE
[2] UNIV PARIS 12,HOP HENRI MONDOR,DEPT EPIDEMIOL,F-94010 CRETEIL,FRANCE
[3] UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT BACTERIOL & VIROL,F-75674 PARIS,FRANCE
[4] ROCHE LABS,F-92521 NEUILLY SUR SEINE,FRANCE
[5] UNIV PARIS 12,HOP HENRI MONDOR,DEPT GASTROENTEROL & HEPATOL,F-94010 CRETEIL,FRANCE
关键词
D O I
10.1089/jir.1995.15.857
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interferon-induced 2',5'-oligoadenylate synthetase (2-5OAS) is responsible, at least in part, for the antiviral state established in cells in response to viral infections, The purpose of this work was to study the relationship between hepatitis C virus (HCV) infection and 2-5OAS in patients with chronic hepatitis C, Peripheral blood mononuclear cells (PBMC) of 27 patients with chronic hepatitis C were investigated, as well as PBMC of 10 control subjects, Then, the patients were treated with 3 mu interferon-alpha(2a) three times per week, At month 3 of therapy, PBMC were sampled, Of the total PBMC samples obtained, half were used for determination of in vivo 2-5OAS activity, The remaining cells were cultured for 24 h in either the absence or presence of 500 U/ml of interferon-alpha(2a) for the determination of in vitro 2-5OAS activity, The mean basal in vivo 2-5OAS activities were 3.6 +/- 2.8 nmol/10(6) cells in patients versus 1.6 +/- 1.1 nmol/10(6) cells in controls (p < 0.01), Basal in vivo 2-5OAS activity did not correlate with mean HCV viremia, quantified by a ''branched DNA''-based assay, Before treatment, interferon-alpha was detected in the serum of 2 patients in 27, After a 24 h culture of PBMC in the presence of interferon, in vitro 2-5OAS activity was significantly induced in the PBMC of both the patients and the controls, However, in vitro induction of 2-5OAS activity was significantly lower in the PBMC of the patients than in the PBMC of the controls (p < 0.01), At month 3 therapy, in vivo 2-5OAS activity was significantly induced (20.5 +/- 17.9; p < 0.0001), In vitro IFN inductions of 2-5OAS activity in PBMC before treatment and at month 3 of therapy were not significantly different. In conclusion, in vivo 2-5OAS activity is significantly induced in patients with chronic hepatitis C, but endogenously produced interferon-alpha does not seem to be involved, Chronic induction of 2-5OAS activity results in a decreased sensitivity of PBMC to exogenous interferon induction, Whether this phenomenon plays a role in the resistance of chronic hepatitis C to interferon therapy remains uncertain.
引用
收藏
页码:857 / 862
页数:6
相关论文
共 41 条
[1]   HIGH-AFFINITY BINDING OF I-125-LABELED MOUSE INTERFERON TO A SPECIFIC CELL-SURFACE RECEPTOR .2. ANALYSIS OF BINDING-PROPERTIES [J].
AGUET, M ;
BLANCHARD, B .
VIROLOGY, 1981, 115 (02) :249-261
[2]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[3]   TIME COURSE OF INTERFERON LEVELS, ANTIVIRAL STATE, 2',5'-OLIGOADENYLATE SYNTHETASE AND SIDE-EFFECTS IN HEALTHY-MEN [J].
BAROUKI, FM ;
WITTER, FR ;
GRIFFIN, DE ;
NADLER, PI ;
WOODS, A ;
WOOD, DL ;
LIETMAN, PS .
JOURNAL OF INTERFERON RESEARCH, 1987, 7 (01) :29-39
[4]   HEPATITIS-C VIRUS IS DETECTED IN A MONOCYTE MACROPHAGE SUBPOPULATION OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF INFECTED PATIENTS [J].
BOUFFARD, P ;
HAYASHI, PH ;
ACEVEDO, R ;
LEVY, N ;
ZELDIS, JB .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1276-1280
[5]   ASSAY AND THE LEVELS OF 2-5A-SYNTHETASE IN LYMPHOCYTES OF PATIENTS WITH VIRAL, BACTERIAL AND AUTOIMMUNE-DISEASES [J].
BUFFETJANVRESSE, C ;
MAGARD, H ;
ROBERT, N ;
HOVANESSIAN, AG .
ANNALES D IMMUNOLOGIE, 1983, D134 (02) :247-258
[6]   HEPATITIS-C SEROTYPE AND RESPONSE TO INTERFERON THERAPY [J].
CHEMELLO, L ;
ALBERTI, A ;
ROSE, K ;
SIMMONDS, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (02) :143-143
[7]  
CHOUSTERMAN S, 1985, BIOMED PHARMACOTHER, V37, P178
[8]   HEPATITIS-C VIRUS GENOTYPES - AN INVESTIGATION OF TYPE-SPECIFIC DIFFERENCES IN GEOGRAPHIC ORIGIN AND DISEASE [J].
DUSHEIKO, G ;
SCHMILOVITZWEISS, H ;
BROWN, D ;
MCOMISH, F ;
YAP, PL ;
SHERLOCK, S ;
MCINTYRE, N ;
SIMMONDS, P .
HEPATOLOGY, 1994, 19 (01) :13-18
[9]   FLUCTUATION OF HEPATITIS-C VIRUS QUASI-SPECIES IN PERSISTENT INFECTION AND INTERFERON TREATMENT REVEALED BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS [J].
ENOMOTO, N ;
KUROSAKI, M ;
TANAKA, Y ;
MARUMO, F ;
SATO, C .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :1361-1369
[10]   2',5'-OLIGOADENYLATE SYNTHETASE-ACTIVITY IN PERIPHERAL-BLOOD LYMPHOCYTES AS A CLINICAL MARKER IN INTERFERON THERAPY FOR CHRONIC HEPATITIS-B [J].
FURUTA, M ;
AKASHI, K ;
NAKAMURA, Y ;
MATSUMOTO, K ;
YAMAGUCHI, H ;
TAKAMATSU, S ;
SHIMIZU, T .
JOURNAL OF INTERFERON RESEARCH, 1987, 7 (01) :111-119